Goal & Strategy

Goal

We will become a profitable and robust business that delivers significant returns to our shareholders by developing and commercializing novel effective therapeutics in oncology.

Strategy for 2012 and beyond

Topotarget strives towards establishing belinostat as one of the most successful HDAC inhibitors in selected indications. In particular, we aim to:

• Finalize the late-stage PTCL and CUP studies
• Submit an NDA to the FDA for belinostat in PTCL together with our partner Spectrum Pharmaceuticals
• Explore commercial opportunities outside the US, including Europe, Asia/Pacific, Latin America, and the rest of the world, in order to maximize the value of belinostat
• Unlock the full potential for belinostat by initiating further clinical studies in the most advantageous indications within hematology and solid tumor oncology, based on the data from the PTCL and CUP studies